Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).

Background

Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually unknown.

Objectives

To evaluate the change in total IgE levels at 4 ± 2 months after initiation of the mepolizumab (primary outcome) or benralizumab. When available, the changes of blood inflammatory cell counts, lung function and asthma control test (ACT) were also assessed and correlated with changes in total IgE levels.

Methods

Observational, retrospective, multicentre, cohort study. Severe eosinophilic atopic asthmatic patients treated with mepolizumab or benralizumab were included in the analysis.

Results

Three-month treatment (on average) with mepolizumab (

Conclusion

Benralizumab but not mepolizumab, treatment led to a significant reduction of circulating IgE level. The study provides different and specific mechanisms of action for anti-IL5-pathway treatments.

Informations de copyright

© 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Déclaration de conflit d'intérêts

Marco Contoli reports grants, personal fees and non‐financial support from Chiesi, personal fees and non‐financial support from AstraZeneca, personal fees and non‐financial support from Boehringer Ingelheim, personal fees and non‐financial support from Alk‐Abello, grants, personal fees and non‐financial support from GlaxoSmithKline, personal fees and non‐financial support from Novartis, personal fees and non‐financial support from Zambon, grants from University of Ferrara, Italy, outside the submitted work. Chiara Martelli reports personal fees and non‐financial support from GSK, Astrazeneca, Novartis, Sanofi outside the submitted work. Alberto Papi reports grants, personal fees, non‐financial support and other from GlaxoSmithKline, grants, personal fees and non‐financial support from AstraZeneca, grants, personal fees, non‐financial support and other from Boehringer Ingelheim, grants, personal fees, non‐financial support and other from Chiesi Farmaceutici, grants, personal fees, non‐financial support and other from TEVA, personal fees, non‐financial support and other from Mundipharma, personal fees, non‐financial support and other from Zambon, personal fees, non‐financial support and other from Novartis, grants, personal fees and non‐financial support from Menarini, personal fees, non‐financial support and other from Sanofi/Regeneron, personal fees from Roche, grants from Fondazione Maugeri, grants from Fondazione Chiesi, personal fees from Edmondpharma, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.